San Diego, CA, October 1, 2025—Denovicon Therapeutics, an AI-driven drug discovery company based in San Diego, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of organizations, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
Scott Bembenek, CEO and Founder of Denovicon, said:
“Becoming a Spoke member of the ARPA-H Investor Catalyst Hub marks an exciting milestone for Denovicon. It affirms our belief that bold science and cutting-edge technology can reshape drug discovery and reflects ARPA-H’s vision for accelerating breakthrough health solutions. Together with ARPA-H and this remarkable community, we are committed to shortening timelines, reducing costs, and bringing transformative therapies to patients faster than ever before.”